{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-002696","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.178851+00:00","generated_at":"2026-05-16T10:55:05.539020+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Passage Bio reports preliminary cash ~$46M as of Dec 31, 2025; runway into Q1 2027","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities of approximately $46 million as of December 31, 2025.","Company expects the cash position to fund operating expenses and capital expenditures into the first quarter of 2027.","Amount is preliminary, subject to completion of year-end financial review, adjustments, and audit."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-002696","json":"https://secwatch.observer/filing/0001104659-26-002696.json","markdown":"https://secwatch.observer/filing/0001104659-26-002696.md","text":"https://secwatch.observer/filing/0001104659-26-002696.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000110465926002696/0001104659-26-002696-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000110465926002696/tm262847d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:55:05.539020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}